Immunovia AB announces outcome of exercise of warrants series TO 2
The exercise period for warrants series TO 2 (the “Warrant Programme”) in Immunovia AB (publ) (“Immunovia” or the “Company”) ended on 16 January 2025. A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 percent. Thus, no guarantee commitments need to be utilized. […]